SAVA - Cassava Sciences - DD - June 2021
Current Price (June 13): 77
O/S 40M
Float 38M
Market cap: ~$3B
Cash ~280M
Burn/year: ~$25M
cassavasciences.com
AD drug - cassavasciences.com/simufilam
Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.
Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.
They also have a blood test to detect AD cassavasciences.com/pti-125dx
Recent updates
O/S 40M
Float 38M
Market cap: ~$3B
Cash ~280M
Burn/year: ~$25M
cassavasciences.com
AD drug - cassavasciences.com/simufilam
Importantly, we do not seek to clear amyloid out of the brain. Our science is based on stabilizing a critical protein in the brain.
Simufilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain.
They also have a blood test to detect AD cassavasciences.com/pti-125dx
Recent updates
- April 21, 2021 - Lots of updates/dates on data releases - Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release - cassavasciences.com/news-relea...
- May 2021 Investor Presentation (must read) - cassavasciences.com/static-fil... and cassavasciences.com/company-pr...
- May 12, 2021 - Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health - cassavasciences.com/news-relea...
Upcoming catalysts
- See stonks.chat/feed/catalysts - they have them in June, July, August, September
- Second interim analysis due to be presented July 26-29 at AAIC meeting.
- They haven't had any news yet in June, so I'm sure an update of some sort is coming. May was a whopper of an update, though.
- Phase 3 study of simufilam in Alzheimer's disease starts in 2nd half 2021.
Heads up
As always, there's two major warnings with any biotech: data could turn out bad (despite expectations otherwise) and offerings are ever looming (since most biotechs have no revenue).
My Notes
This one has a lot going for it, but $3B feels like a hefty valuation at this stage based on what I currently new (though I'm new on this one). I need to do a little more homework. I've traded this a few times, but I'll likely have a position going into summer data releases (starting in July).
Comments
Login to join the discussion!
Maverick - 2 years ago
Update PR on June 21, 2021
- Open-label Study Completes Patient Enrollment
- Cognition Maintenance Study Initiated May 2020, now 30% Enrolled
- 6-month Biomarker Data to be Presented at AAIC Conference in July
- 9-month Safety & Cognition Data to be Presented at AAIC Conference
- Clinical Results with SavaDx to be Presented at AAIC Conference
- Phase 3 Program Initiation Remains On-track for 2nd Half 2021
0
Maverick - 2 years ago
May 2021 Investor Presentation (must read) - cassavasciences.com/static-fil...
Cassava Sciences - SAVA
| Total Followers: | 1 |
|
|
|
| Follow | |